Latest Research And Development News

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Nanoveu Limited’s transformative half-year report highlights its EMASS acquisition, executive hires, and technology advances amid a $3 million loss and new US OTCQB listing.

FBR Ltd reported a 57% revenue increase driven by property sales but posted a $29 million loss as it advances commercialization of its Hadrian X® robotic bricklayer and secures significant new funding.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

ClearVue Technologies reported a striking 553% revenue increase to nearly $250,000 in FY2025, alongside a 7% reduction in net loss, driven by strategic partnerships and global project wins.

Codeifai Limited reported a near doubling of its half-year loss to $3.93 million, alongside a 32% revenue drop, while pursuing transformative AI and quantum security acquisitions and securing $2.35 million in fresh capital.

Papyrus Australia reported a July 2025 cash flow update showing a stable cash position of AUD 303,000 and available funding supporting operations for over eight months. The company continues to manage its financing facilities prudently while navigating operational expenses.

Senetas Corporation reported a substantial $27.8 million net profit for FY2025, driven by the strategic sale of its Votiro business. The company also announced plans for a capital return and a major share consolidation ahead of a promising growth outlook.

Senetas Corporation has reported a transformative FY2025 with a $27.8 million net profit driven by the divestment of its Votiro business, while its core network encryption operations remain profitable and cash generative.